CLDX Company Profile and Key Details

Q: Who are the executives of CLDX?

Mr. Anthony S. Marucci M.B.A.Founder, Pres, Chief Executive Officer & DirectorDr. Tibor KelerFounder, Chief Scientific Officer & Executive Vice PresidentProf. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Sarah CavanaughSenior Vice President of Corporation Affairs & Admin.Mr. Freddy A. Jimenez Esq.Senior Vice President & Gen. CounselDr. Diane C. Young M.D.Senior Vice President & Chief Medical OfficerMr. Sam MartinSenior Vice President, Chief Financial Officer, Sec. & TreasurerPatrick TillSenior Director of Investor Relations & Corporation CommunicationsMs. Elizabeth CrowleyChief Product Devel. Officer & Senior Vice PresidentDr. Ronald A. PepinChief Bus. Officer & Senior Vice PresidentDr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs

NASDAQ : CLDX

Celldex Therapeutics

$34.55

0.0029+0.01%

Open: 12:50 PM

66.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Celldex Therapeutics, Inc. (CLDX) stock surged +0.01%, trading at $34.55 on NASDAQ, up from the previous close of $34.55. The stock opened at $35.79, fluctuating between $34.34 and $35.79 in the recent session.

Stock Snapshot

34.55

Prev. Close

2.3B

Market Cap

34.34

Day Low

-8.86

P/E Ratio

-3.9

EPS (TTM)

-2.1

Cash Flow per Share

35.79

Open

66.57M

Number of Shares

35.79

Day High

97.16%

Free Float in %

8.25

Book Value

410.46K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2026	34.55	35.29	34.32	34.55	1.48M
Apr 16, 2026	33.82	33.97	33.28	33.86	852.73K
Apr 14, 2026	32.23	33.72	31.97	33.33	844.26K
Apr 13, 2026	32.31	32.83	32.11	32.59	691.12K
Apr 10, 2026	33.60	33.73	32.08	32.24	696.12K
Apr 09, 2026	32.45	33.86	32.23	33.62	815.38K
Apr 08, 2026	31.97	32.59	31.04	32.41	1.78M
Apr 07, 2026	30.96	31.62	30.52	31.35	1.88M
Apr 06, 2026	31.77	32.32	30.88	31.37	1.92M
Apr 02, 2026	29.31	31.39	28.41	31.06	5.17M
Apr 01, 2026	31.94	32.61	31.14	31.26	412.66K
Mar 31, 2026	30.48	32.42	30.46	31.72	1.37M
Mar 30, 2026	30.24	30.67	29.30	29.48	649.28K
Mar 27, 2026	31.29	31.75	30.00	30.30	904.82K
Mar 25, 2026	31.77	32.44	31.39	31.68	657K
Mar 24, 2026	31.40	31.97	30.50	31.19	932.97K
Mar 23, 2026	32.80	34.52	31.73	31.80	1.46M
Mar 20, 2026	30.26	31.85	29.95	30.90	3.17M
Mar 19, 2026	28.18	30.45	27.92	30.03	1.03M
Mar 18, 2026	29.38	29.72	28.40	28.54	720.11K

Contact Details

Hampton, NJ 08827

United States

https://www.celldex.com 908 200 7500

About Company

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed at $34.59 USD, gaining $0.04 (0.12%) from the previous close of $34.55. The stock is currently within 5% of its 52-week high $17.85 and $35.79. With a market capitalization of about $2.30 billion, Celldex Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.20). Key stats such as the average daily volume over the past year has been around 1.01 million shares, volume is running light vs its 52-week average. Headquartered in Hampton, NJ, Celldex Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anthony S. Marucci, the company employs approximately 186 people and listed since May 15, 1986. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 24.18%, SMA50 19.42%, SMA200 27.01%). The stock’s 14-day RSI is 71.47 (overbought), while the ATR of 1.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.16% below its high and over 112.78% above its low. Average 10-day trading volume of 913.07 thousand shares is in line with the 3-month average of 997.11 thousand, indicating normal recent market interest.

Valuation Metrics

Celldex Therapeutics, Inc. trades at a P/E ratio of -8.88, slightly below the S&P 500 average, with a price-to-sales ratio of 1533.31 and a price-to-book ratio of 4.36 trading at moderately above to book value. The P/FCF stands at -10.78, also below market averages.

Dividend & Fair Value

Celldex Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.08. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Celldex Therapeutics, Inc. generated EPS of -$3.38 over the past year. Five-year average earnings growth is 6.91%. Wall Street analysts project EPS growth of 1.41% annually over the next five years. The latest quarter delivered EPS of -$1.01. The next quarter is forecast at -$1.08. Next year's EPS is expected at -$10.48. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $68.00 to $21.00. The high target offers 96.82% upside. The low target suggests -39.22% downside. The mean target is $43.67. This offers 26.4% upside. Celldex Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 14.77%. The prior quarter beat by -1.16%. Over the last six quarters, Apple has recorded several small beats. These include -8.47% in August 08, 2024.

Shareholding & Insider Activity

Celldex Therapeutics, Inc. has 66.41 million shares outstanding. The public float is 53.21 million shares, elevated short interest at 13.01% of float. This equals 7.31 million shares. The short ratio is 7.07 days. Institutional investors hold 111.54% of the float. Insiders own 0.19%. MEDAREX INC holds 2.96 million shares, ELLBERGER LARRY has 53.50 thousand shares and Marucci Anthony S has 40.28 thousand shares. Over the past six months, insider transactions show net selling. They sold 53.46 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Celldex Therapeutics generated $6.88M in revenue, or $0.14 per share. Gross margin was 56.30%, operating margin -2063.66%, and net profit margin -2054.76%. Returns are negative, with ROA at -30.37% and ROE at -32.95%.
On valuation metrics, Celldex Therapeutics trades at a P/E of -8.88, P/S of 1533.31 and P/B of 4.36. The current ratio is 10.49 and quick ratio is 10.49. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 490.32 days. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -90.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Celldex Therapeutics posted revenue of $6.88M, down slightly from $2.36M in the prior quarter. Gross profit was $3.88M (margin 56.30%). Operating income was - $142.04M (margin -2063.7%). Net income was- $141.43M (EPS - $2.92).
The company ended the quarter with $421.70M in cash and short-term investments, a total debt of $2.54M, and net debt of - $32.27M. Total assets were $465.63M, with equity of $429.17M. Financials further reflected weakness, with operating cash flow of - $107.29M, free cash flow of - $109.11M, and capital expenditures of - $1.82M.

Price Forecast & Outlook

Our AI price prediction model suggests that Celldex Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.34%, with price expected at $35.36 by May 01, 2026, within a range of $33.76 to $37.06 3-Month Outlook: Projected rise of 101.22%, reaching $69.52 by July 16, 2026, with a range of $67.04 to $72.02. 1-Year Outlook: Projected loss of -13.78%, with price at $29.79 by April 16, 2027, within a range of $27.23 to $32.08.

Key Takeaways

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares are flat -7.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Celldex Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.88. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $53.95, suggesting 56.15% upside. Our AI forecast model points to short-term strength (2.34% over two weeks), a medium-term rise (101.22% over three months), and a longer-term loss (-13.78% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Celldex Therapeutics, Inc. (CLDX) stock price?

Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock price is $34.55 in the last trading session. During the trading session, CLDX stock reached the peak price of $35.79 while $34.34 was the lowest point it dropped to. The percentage change in CLDX stock occurred in the recent session was 0.01% while the dollar amount for the price change in CLDX stock was $0.00.

CLDX's industry and sector of operation?

The NASDAQ listed CLDX is part of Biotechnology industry that operates in the broader Healthcare sector. Celldex Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLDX?

Mr. Anthony S. Marucci M.B.A.
Founder, Pres, Chief Executive Officer & Director
Dr. Tibor Keler
Founder, Chief Scientific Officer & Executive Vice President
Prof. Joseph P. Schlessinger Ph.D.
Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh
Senior Vice President of Corporation Affairs & Admin.
Mr. Freddy A. Jimenez Esq.
Senior Vice President & Gen. Counsel
Dr. Diane C. Young M.D.
Senior Vice President & Chief Medical Officer
Mr. Sam Martin
Senior Vice President, Chief Financial Officer, Sec. & Treasurer
Patrick Till
Senior Director of Investor Relations & Corporation Communications
Ms. Elizabeth Crowley
Chief Product Devel. Officer & Senior Vice President
Dr. Ronald A. Pepin
Chief Bus. Officer & Senior Vice President
Dr. Margo Heath-Chiozzi M.D.
Senior Vice President of Regulatory Affairs

How CLDX did perform over past 52-week?

CLDX's closing price is 93.56% higher than its 52-week low of $17.85 where as its distance from 52-week high of $35.79 is -2.08%.

How many employees does CLDX have?

Number of CLDX employees currently stands at 186.

Link for CLDX official website?

Official Website of CLDX is: https://www.celldex.com

How do I contact CLDX?

CLDX could be contacted at phone 908 200 7500 and can also be accessed through its website. CLDX operates from Perryville III Building, Hampton, NJ 08827, United States.

How many shares of CLDX are traded daily?

CLDX stock volume for the day was 410.46K shares. The average number of CLDX shares traded daily for last 3 months was 1.19M.

What is the market cap of CLDX currently?

The market value of CLDX currently stands at $2.30B with its latest stock price at $34.55 and 66.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	186
Beta	1.2
Sales or Revenue	$6.88M
5Y Sales Change%	-0.844%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CLDX Company Profile and Key Details

Celldex Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights